Abstract
KILLED Corynebacterium parvum has been effective when administered into tumours or when included as a subcutaneous inoculum containing tumour cells (the subcutaneous site, unlike the intradermal site1, facilitates early tumour cell dissemination)2–4. After tumour rejection, the augmented host resistance prevented progressive growth of potentially lethal metastases present at the time of therapy5. In addition, animals rejecting tumours formed from primary grafts of tumour cells admixed with killed C. parvum (compared with those rejecting tumours after intratumour therapy with C. parvum) exhibited an augmented tumour-specific protection against inoculation of large challenge cell doses6. Whitmire and Huebner7 reported a significant decrease in incidence of 3-methyl-cholanthrene-induced malignancies in C57BL/Cum and BALB/c Cv mice after preimmunisation with formalin-killed wild-type virus and Rauscher leukaemia virus vaccines administered with Freund's complete adjuvant. We have now found a considerable decrease in the incidence of spontaneous tumours in the high-incidence strain of DBA/2 mice after rejection of tumours formed from subcutaneous transplants of syngeneic mammary adenocarcinoma cells admixed with killed C. parvum.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Gross, L., Cancer Res., 3, 326–336 (1943).
Likhite, V. V., and Halpern, B. N., Int. J. Cancer, 12, 699–704 (1973).
Likhite, V. V., and Halpern, B. N., Cancer Res., 34, 341–344 (1974).
Paslin, D., Dimitrov, N. V., and Heaton, C., J. natn. Cancer Inst., 52, 571–573 (1974).
Likhite, V. V., Int. J. Cancer, 14, 684–690 (1974).
Likhite, V. V., in Corynebacterium parvum: Applications in Experimental and Clinical Oncology (Plenum, New York, in the press).
Whitmire, C. E., and Huebner, R. J., Science, 177, 60–63 (1972).
Likhite, V. V., Cancer Res., 34, 2790–2794 (1974).
Glynn, J. P., Bianco, A. R., and Goldin, A., Cancer Res., 24, 502–508 (1964).
Sachs, L., J. natn. Cancer Inst., 29, 759–764 (1962).
Johnson, N., and Sjögren, H. O., J. exp. Med., 122, 403–421 (1965).
Lavrin, D. H., Blair, P. B., and Weiss, D. W., Cancer Res., 26, 929–934 (1966).
Klein, G., Sjögren, H., and Klein, E., Cancer Res., 22, 955–961 (1962).
Klein, E., and Klein, G., J. natn. Cancer Inst., 32, 547–568 (1964).
Klein, G., Fedn Proc., 28, 1739 (1969).
Holmes, E. C., Kahan, B. D., and Morton, D. L., Cancer, 25, 373–379 (1970).
Kronman, B. S., et al., Science, 168, 257–259 (1970).
Eilber, F. R., Holmes, D., and Morton, D. L., J. natn. Can. Inst., 46, 803–808 (1971).
Halpern, B., et al., in CIBA Foundation Symp.: Immunopotentiation, 217–234 (Elsevier, North Holland, Amsterdam, 1973).
Howard, H. G., Scott, M. T., and Christie, G. H., in CIBA Foundation Symp.: Immunopotentiation, 101–120 (Elsevier, North Holland, Amsterdam, 1973).
Likhite, V. V., J. Immun., 114, 1736–1742 (1975).
Frost, P., and Lance, E. M., in CIBA Foundation Symp.: Immunopotentiation, 29–38 (Elsevier, North Holland, Amsterdam, 1973).
Biozzi, G., Howard, J. G., Mouton, D., and Stiffel, C., Transplantation, 3, 170–177 (1965).
Lamensans, A. C., et al., Revue fr. Etud. clin Biol., 13, 773–779 (1968).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
LIKHITE, V. Suppression of the incidence of death with spontaneous tumours in DBA/2 mice after Corynebacterium parvum-mediated rejection of syngeneic tumours. Nature 259, 397–399 (1976). https://doi.org/10.1038/259397a0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/259397a0
This article is cited by
-
Local immunotherapy of stomach and intestinal carcinoma by Propionibacterium granulosum
Diseases of the Colon & Rectum (1980)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.